Author: Almeida, Dennys Ramon de Melo Fernandes ; Santos, Pedro Paulo de Andrade ; de França, Glória Maria ; Pinheiro, Juliana Campos ; Lima, Jabes Gennedyr da Cruz ; Medeiros, Cristianne Kalinne Santos

AbstractIntroductionSeveral treatments have been used to reduce inflammation and to reverse epithelial alterations in actinic cheilitis (AC).AimA systematic review was conducted to analyze the potential of topical treatments for remission and clinical improvement of AC as well as patient acceptability.MethodsA systematic review of clinical trials was conducted following the PICO strategy to answer the following question: Are topical anti‐inflammatory and antineoplastic agents effective in the treatment of actinic cheilitis? The quality of the studies was assessed by ROB‐2, and the certainty of evidence was rated by GRADE guidelines.ResultsEight clinical trials were selected, including four that investigated the use of anti‐inflammatory drugs and four use of antineoplastic agents. The use of 3% diclofenac sodium was associated with partial remission of AC, while 5% imiquimod and ingenol mebutate promoted complete remission. Furthermore, 5% fluorouracil was the drug most associated with complications during treatment. Diclofenac sodium (3%) and fludroxycortide showed the best acceptance by the patients, especially in terms of symptom relief and comfort provided.ConclusionThe anti‐inflammatory and antineoplastic agents analyzed largely provided good clinical outcomes, with evidence of remission of AC lesions, development of few local adverse reactions during treatment, and good patient adherence.

01 Aug 2020·Dermatologic SurgeryQ3 · MEDICINE

Combination of 1,064-nm Neodymium-doped Yttrium Aluminum Garnet Laser and Steroid Tape Decreases the Total Treatment Time of Hypertrophic Scars: An Analysis of 40 Cases of Cesarean-Section Scars

Q3 · MEDICINE

Article

Author: An-Jou Lin, Jennifer ; Tsai, Chia-Hsuan ; Ogawa, Rei ; Akaishi, Satoshi ; Kao, Huang-Kai

BACKGROUNDThe 1,064-nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser (Cutera, Inc., Brisbane, CA) and steroid tape (fludroxycortide tape) have been used to treat keloids and hypertrophic scars.OBJECTIVETo evaluate the efficacy of contact-mode 1,064-nm Nd:YAG laser therapy and steroid tape for hypertrophic cesarean-section scars versus conservative therapy (steroid tape only).MATERIALS AND METHODSA medical record review identified 40 consecutive Japanese patients who had hypertrophic scars (total Japan Scar Workshop Scar Scale [JSS] 2015 evaluation scores of 9 to 12) for more than 1 year after a vertical cesarean section and who were treated at our scar-specialist clinic from July 2015 to December 2017. All 40 patients continued treatment until the total JSS score dropped below 3. Recurrence was defined as a ≥1-point increase in the total JSW score 6 months after achieving a total JSS score <3.RESULTSThe patients had a mean age of 34.2 years. The test (n = 25) and control (n = 15) groups took on average 16.9 and 24.3 months to achieve a total JSS score <3, respectively (p < .01). In the following 6 months, none of the scars recurred.CONCLUSIONNd:YAG laser treatment effectively decreased the total treatment time of hypertrophic cesarean-section scars. An algorithm for treating mild and severe hypertrophic cesarean-section scars is proposed.

01 Oct 2019·Clinical Oral InvestigationsQ2 · MEDICINE

Fludroxycortide cream as an alternative therapy for actinic cheilitis

Q2 · MEDICINE

Article

Author: Gonzaga, Amanda Katarinny Goes ; de Oliveira, Patrícia Teixeira ; da Silveira, Éricka Janine Dantas ; de Medeiros, Ana Miryam Costa ; de Oliveira Bezerra, Hanna Isa

OBJECTIVESThe objective of the study is to assess, by clinical follow-up, the efficacy of the dermatological cream Fludroxycortide 0.125 mg/g (Drenison®) in the treatment of actinic cheilitis (AC).MATERIAL AND METHODSTwenty-three patients diagnosed with AC participated in the study. Fifteen were submitted to corticotherapy with Fludroxycortide, applied three times a day for up to 6 weeks, associated with lip sunscreen (LS) before sun exposure. In the control group of eight patients, only the use of LS was established. At each weekly return, a photographic record was made of the lesion. After treatment, images were evaluated and scores were assigned to verify clinical evolution. Also, patients treated with Fludroxycortide responded to a questionnaire, to assess drug tolerability and treatment satisfaction.RESULTSIn the group treated with Fludroxycortide (n = 15), five patients showed total improvement, seven presented partial improvement, and three showed no clinical change. Concerning the patients treated with LS (n = 8), one presented total remission of the clinical lesion characteristics, four exhibited partial improvement, and three exhibited no clinical lip alteration. No case presented symptom worsening. Of the 15 patients undergoing corticotherapy, 12 were satisfied and reported that the product was not irritating and contributed to lesion improvement.CONCLUSIONSConventional treatment with LS was effective in the remission of some AC lesions, but treatment responses were improved when associated with Fludroxycortide, especially in the more severe cases.CLINICAL RELEVANCEAs it is a non-invasive therapy leading, in most cases, to adequate clinical results, safety, and tolerability, Fludroxycortide can be considered an effective alternative treatment for AC.

100 Deals associated with Flurandrenolide

External Link

KEGG	Wiki	ATC	Drug Bank
D00328	Flurandrenolide	D07AC07	DB00846

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Amyloidosis, Primary Cutaneous	JP	Sumitomo Pharma Co., Ltd.	31 Aug 1981
Cicatrix, Hypertrophic	JP	Sumitomo Pharma Co., Ltd.	31 Aug 1981
Fox-Fordyce Disease	JP	Sumitomo Pharma Co., Ltd.	31 Aug 1981
Granuloma Annulare	JP	Sumitomo Pharma Co., Ltd.	31 Aug 1981
Keloid	JP	Sumitomo Pharma Co., Ltd.	31 Aug 1981
Lichen Nitidus	JP	Sumitomo Pharma Co., Ltd.	31 Aug 1981
Lymphoma	JP	Sumitomo Pharma Co., Ltd.	31 Aug 1981
Vitiligo	JP	Sumitomo Pharma Co., Ltd.	31 Aug 1981
Eczema	JP	Sumitomo Pharma Co., Ltd.	01 Apr 1972
Lichen Planus	JP	Sumitomo Pharma Co., Ltd.	01 Apr 1972
Lupus Erythematosus, Discoid	JP	Sumitomo Pharma Co., Ltd.	01 Apr 1972
prurigo nodularis	JP	Sumitomo Pharma Co., Ltd.	01 Apr 1972
Psoriasis	JP	Sumitomo Pharma Co., Ltd.	01 Apr 1972

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis